Back to mobile site

Regeneron Pharma (REGN) May Have Upside From Taxes - Analyst

February 11, 2014 10:36 AM EST Send to a Friend
Deutsche Bank maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) with a price target of $375.00. The company earlier ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login